Prognostic value of KI ‐67, MIPI score and SUV MAX of the PET scan: Result of a single center experience with mantle‐cell lymphomas
Article Swipe
Thi Thuy Dung Nguyen
,
Alexandre de Wind
,
Erwin Woff
,
Peter Heimann
,
Marie Vercruyssen
,
Chloé Spilleboudt
,
Marie Maerevoet
,
Nathalie Meuleman
,
Brigitte Cantinieaux
,
Stefan Michiels
,
Dominique Bron
·
YOU?
·
· 2017
· Open Access
·
· DOI: https://doi.org/10.1002/hon.2439_111
YOU?
·
· 2017
· Open Access
·
· DOI: https://doi.org/10.1002/hon.2439_111
Introduction: Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma with highly variable behaviors in terms of survival data. Recently, the European Mantle Cell Lymphoma Network reported that the Ki-67 index combined with MIPI allows refining the risk stratification. Beside these 2 complementary prognostic factors, the role of 18-fluorodeoxyglucose (FDG)-positron emission tomography (PET) and primarily the level of maximum standardized uptake value (SUVmax) (hyper metabolic activity) is poorly investigated in the literature. Population and Methods: We thus retrospectively reviewed 65 MCL patients admitted in our Institute for treatment. Pathological, phenotypical and cytogenetic data were independently reviewed. MIPI scores (according to E. Hoster, BLOOD 2008) and Ki-67 index (according to published guidelines) were calculated. When available, 18-FDG PET/CT scan at diagnosis was reviewed to determine maximal SUV. Patients were then stratified according to the MIPI scores and High, Low and intermediate risk groups were correlated with the maximum SUV. Overall survival was evaluated by Cox regression model. Results: Fifty-three patients (pts) were evaluable for MIPI score and outcome, Ki-67 index value was available in 30 pts and 24 pts had a PET/CT scan at diagnosis. Median age at diagnosis was 62 (40-85) years old. In the low risk group (MIPI 0-3), median age was 61 (42-77 years old, median overall survival (OS) was 148 Months (Mo), median SUV max was 2.86 (2.0-8.4) and 4% had Ki-67 > 30%. In the intermediate risk group (MIPI, 4-5) median age was 65 (54-79) y.o., median OS was 63 Mo, median SUV max was 6.31 (4.7-10.4) and Ki-67 was >30% in 36% of the pts. In the high-risk group (MIPI 6+) median age was 71 (47-85) y.o, median OS was 36 Mo, median SUV max was 8.25 (2.0-15.6) and Ki67 > 30% in 57%. In the “blastoïd” MCL group, median age was 58 (40-77) years old median OS was 57 Mo, median SUV max was 13.9 (2.6-23.1) and 40% had Ki67 > 30%. Interestingly before the era of Ibrutinib treatment, Ki-67 index had an independent prognostic value that disappears after treatment with anti-BTK. Conclusion: Our small series of MCL confirms the prognostic value of MIPI scores (med OS of 148, 63 and 36 months in High, intermediate and Low risks pts respectively) and poor outcome of blastoïd histology (med OS 57 mo). The median SUV max value of the initial 18-FGD PET/CT was higher in the high risk and blastoïd MCLs and a high SUV seems to correlate with a poor outcome. However, in the era of very effective treatment such as Ibrutinib, these prognostic markers deserves confirmation in wider series. Keywords: mantle cell lymphoma (MCL); positron emission tomography (PET); prognostic indices
Related Topics
Concepts
Medicine
International Prognostic Index
Mantle cell lymphoma
Single Center
Standardized uptake value
Population
Lymphoma
Nuclear medicine
Proportional hazards model
Positron emission tomography
Proliferation index
Internal medicine
Gastroenterology
Diffuse large B-cell lymphoma
Immunohistochemistry
Environmental health
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1002/hon.2439_111
- https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hon.2439_111
- OA Status
- bronze
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W2622491763
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W2622491763Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1002/hon.2439_111Digital Object Identifier
- Title
-
Prognostic value of
KI ‐67,MIPI score and SUV MAX of thePET scan: Result of a single center experience with mantle‐cell lymphomasWork title - Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2017Year of publication
- Publication date
-
2017-06-01Full publication date if available
- Authors
-
Thi Thuy Dung Nguyen, Alexandre de Wind, Erwin Woff, Peter Heimann, Marie Vercruyssen, Chloé Spilleboudt, Marie Maerevoet, Nathalie Meuleman, Brigitte Cantinieaux, Stefan Michiels, Dominique BronList of authors in order
- Landing page
-
https://doi.org/10.1002/hon.2439_111Publisher landing page
- PDF URL
-
https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hon.2439_111Direct link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
bronzeOpen access status per OpenAlex
- OA URL
-
https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hon.2439_111Direct OA link when available
- Concepts
-
Medicine, International Prognostic Index, Mantle cell lymphoma, Single Center, Standardized uptake value, Population, Lymphoma, Nuclear medicine, Proportional hazards model, Positron emission tomography, Proliferation index, Internal medicine, Gastroenterology, Diffuse large B-cell lymphoma, Immunohistochemistry, Environmental healthTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W2622491763 |
|---|---|
| doi | https://doi.org/10.1002/hon.2439_111 |
| ids.doi | https://doi.org/10.1002/hon.2439_111 |
| ids.mag | 2622491763 |
| ids.openalex | https://openalex.org/W2622491763 |
| fwci | 0.0 |
| type | article |
| title | Prognostic value of |
| biblio.issue | S2 |
| biblio.volume | 35 |
| biblio.last_page | 357 |
| biblio.first_page | 357 |
| topics[0].id | https://openalex.org/T10185 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9977999925613403 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2734 |
| topics[0].subfield.display_name | Pathology and Forensic Medicine |
| topics[0].display_name | Lymphoma Diagnosis and Treatment |
| topics[1].id | https://openalex.org/T10417 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9764999747276306 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2740 |
| topics[1].subfield.display_name | Pulmonary and Respiratory Medicine |
| topics[1].display_name | Lung Cancer Treatments and Mutations |
| topics[2].id | https://openalex.org/T11067 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9625999927520752 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2730 |
| topics[2].subfield.display_name | Oncology |
| topics[2].display_name | Colorectal Cancer Treatments and Studies |
| is_xpac | False |
| apc_list.value | 4220 |
| apc_list.currency | USD |
| apc_list.value_usd | 4220 |
| apc_paid | |
| concepts[0].id | https://openalex.org/C71924100 |
| concepts[0].level | 0 |
| concepts[0].score | 0.7814912796020508 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[0].display_name | Medicine |
| concepts[1].id | https://openalex.org/C2778476033 |
| concepts[1].level | 4 |
| concepts[1].score | 0.7195764780044556 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q1667625 |
| concepts[1].display_name | International Prognostic Index |
| concepts[2].id | https://openalex.org/C2777525834 |
| concepts[2].level | 3 |
| concepts[2].score | 0.6776673197746277 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q268713 |
| concepts[2].display_name | Mantle cell lymphoma |
| concepts[3].id | https://openalex.org/C2780073493 |
| concepts[3].level | 2 |
| concepts[3].score | 0.5743980407714844 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q7523837 |
| concepts[3].display_name | Single Center |
| concepts[4].id | https://openalex.org/C199374082 |
| concepts[4].level | 3 |
| concepts[4].score | 0.5465991497039795 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q907080 |
| concepts[4].display_name | Standardized uptake value |
| concepts[5].id | https://openalex.org/C2908647359 |
| concepts[5].level | 2 |
| concepts[5].score | 0.501028299331665 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q2625603 |
| concepts[5].display_name | Population |
| concepts[6].id | https://openalex.org/C2779338263 |
| concepts[6].level | 2 |
| concepts[6].score | 0.48657310009002686 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q208414 |
| concepts[6].display_name | Lymphoma |
| concepts[7].id | https://openalex.org/C2989005 |
| concepts[7].level | 1 |
| concepts[7].score | 0.4762980043888092 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q214963 |
| concepts[7].display_name | Nuclear medicine |
| concepts[8].id | https://openalex.org/C50382708 |
| concepts[8].level | 2 |
| concepts[8].score | 0.44212037324905396 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q223218 |
| concepts[8].display_name | Proportional hazards model |
| concepts[9].id | https://openalex.org/C2775842073 |
| concepts[9].level | 2 |
| concepts[9].score | 0.43789488077163696 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q208376 |
| concepts[9].display_name | Positron emission tomography |
| concepts[10].id | https://openalex.org/C2910938049 |
| concepts[10].level | 3 |
| concepts[10].score | 0.4132840633392334 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q7249605 |
| concepts[10].display_name | Proliferation index |
| concepts[11].id | https://openalex.org/C126322002 |
| concepts[11].level | 1 |
| concepts[11].score | 0.4057386517524719 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[11].display_name | Internal medicine |
| concepts[12].id | https://openalex.org/C90924648 |
| concepts[12].level | 1 |
| concepts[12].score | 0.38204509019851685 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q120569 |
| concepts[12].display_name | Gastroenterology |
| concepts[13].id | https://openalex.org/C2778559949 |
| concepts[13].level | 3 |
| concepts[13].score | 0.34407103061676025 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q2626074 |
| concepts[13].display_name | Diffuse large B-cell lymphoma |
| concepts[14].id | https://openalex.org/C204232928 |
| concepts[14].level | 2 |
| concepts[14].score | 0.188806414604187 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q899285 |
| concepts[14].display_name | Immunohistochemistry |
| concepts[15].id | https://openalex.org/C99454951 |
| concepts[15].level | 1 |
| concepts[15].score | 0.0 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q932068 |
| concepts[15].display_name | Environmental health |
| keywords[0].id | https://openalex.org/keywords/medicine |
| keywords[0].score | 0.7814912796020508 |
| keywords[0].display_name | Medicine |
| keywords[1].id | https://openalex.org/keywords/international-prognostic-index |
| keywords[1].score | 0.7195764780044556 |
| keywords[1].display_name | International Prognostic Index |
| keywords[2].id | https://openalex.org/keywords/mantle-cell-lymphoma |
| keywords[2].score | 0.6776673197746277 |
| keywords[2].display_name | Mantle cell lymphoma |
| keywords[3].id | https://openalex.org/keywords/single-center |
| keywords[3].score | 0.5743980407714844 |
| keywords[3].display_name | Single Center |
| keywords[4].id | https://openalex.org/keywords/standardized-uptake-value |
| keywords[4].score | 0.5465991497039795 |
| keywords[4].display_name | Standardized uptake value |
| keywords[5].id | https://openalex.org/keywords/population |
| keywords[5].score | 0.501028299331665 |
| keywords[5].display_name | Population |
| keywords[6].id | https://openalex.org/keywords/lymphoma |
| keywords[6].score | 0.48657310009002686 |
| keywords[6].display_name | Lymphoma |
| keywords[7].id | https://openalex.org/keywords/nuclear-medicine |
| keywords[7].score | 0.4762980043888092 |
| keywords[7].display_name | Nuclear medicine |
| keywords[8].id | https://openalex.org/keywords/proportional-hazards-model |
| keywords[8].score | 0.44212037324905396 |
| keywords[8].display_name | Proportional hazards model |
| keywords[9].id | https://openalex.org/keywords/positron-emission-tomography |
| keywords[9].score | 0.43789488077163696 |
| keywords[9].display_name | Positron emission tomography |
| keywords[10].id | https://openalex.org/keywords/proliferation-index |
| keywords[10].score | 0.4132840633392334 |
| keywords[10].display_name | Proliferation index |
| keywords[11].id | https://openalex.org/keywords/internal-medicine |
| keywords[11].score | 0.4057386517524719 |
| keywords[11].display_name | Internal medicine |
| keywords[12].id | https://openalex.org/keywords/gastroenterology |
| keywords[12].score | 0.38204509019851685 |
| keywords[12].display_name | Gastroenterology |
| keywords[13].id | https://openalex.org/keywords/diffuse-large-b-cell-lymphoma |
| keywords[13].score | 0.34407103061676025 |
| keywords[13].display_name | Diffuse large B-cell lymphoma |
| keywords[14].id | https://openalex.org/keywords/immunohistochemistry |
| keywords[14].score | 0.188806414604187 |
| keywords[14].display_name | Immunohistochemistry |
| language | en |
| locations[0].id | doi:10.1002/hon.2439_111 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S23714410 |
| locations[0].source.issn | 0278-0232, 1099-1069 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 0278-0232 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Hematological Oncology |
| locations[0].source.host_organization | https://openalex.org/P4310320595 |
| locations[0].source.host_organization_name | Wiley |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320595 |
| locations[0].source.host_organization_lineage_names | Wiley |
| locations[0].license | |
| locations[0].pdf_url | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hon.2439_111 |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Hematological Oncology |
| locations[0].landing_page_url | https://doi.org/10.1002/hon.2439_111 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5026688698 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-1810-4786 |
| authorships[0].author.display_name | Thi Thuy Dung Nguyen |
| authorships[0].countries | BE |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I2801838318 |
| authorships[0].affiliations[0].raw_affiliation_string | Hematology, Institut Jules Bordet, ULB, Brussels, Belgium |
| authorships[0].institutions[0].id | https://openalex.org/I2801838318 |
| authorships[0].institutions[0].ror | https://ror.org/05e8s8534 |
| authorships[0].institutions[0].type | healthcare |
| authorships[0].institutions[0].lineage | https://openalex.org/I2801838318 |
| authorships[0].institutions[0].country_code | BE |
| authorships[0].institutions[0].display_name | Institut Jules Bordet |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | T. Nguyen |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Hematology, Institut Jules Bordet, ULB, Brussels, Belgium |
| authorships[1].author.id | https://openalex.org/A5074586183 |
| authorships[1].author.orcid | |
| authorships[1].author.display_name | Alexandre de Wind |
| authorships[1].countries | BE |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I2801838318 |
| authorships[1].affiliations[0].raw_affiliation_string | Pathology, Institut Jules Bordet, ULB, Brussels, Belgium |
| authorships[1].institutions[0].id | https://openalex.org/I2801838318 |
| authorships[1].institutions[0].ror | https://ror.org/05e8s8534 |
| authorships[1].institutions[0].type | healthcare |
| authorships[1].institutions[0].lineage | https://openalex.org/I2801838318 |
| authorships[1].institutions[0].country_code | BE |
| authorships[1].institutions[0].display_name | Institut Jules Bordet |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | A. de Wind |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Pathology, Institut Jules Bordet, ULB, Brussels, Belgium |
| authorships[2].author.id | https://openalex.org/A5087830871 |
| authorships[2].author.orcid | https://orcid.org/0000-0001-9290-8929 |
| authorships[2].author.display_name | Erwin Woff |
| authorships[2].countries | BE |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I2801838318 |
| authorships[2].affiliations[0].raw_affiliation_string | Nuclear Medicine, Institut Jules Bordet, ULB, Brussels, Belgium |
| authorships[2].institutions[0].id | https://openalex.org/I2801838318 |
| authorships[2].institutions[0].ror | https://ror.org/05e8s8534 |
| authorships[2].institutions[0].type | healthcare |
| authorships[2].institutions[0].lineage | https://openalex.org/I2801838318 |
| authorships[2].institutions[0].country_code | BE |
| authorships[2].institutions[0].display_name | Institut Jules Bordet |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | E. Woff |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Nuclear Medicine, Institut Jules Bordet, ULB, Brussels, Belgium |
| authorships[3].author.id | https://openalex.org/A5018716666 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | Peter Heimann |
| authorships[3].countries | BE |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I2801838318 |
| authorships[3].affiliations[0].raw_affiliation_string | Molecular Biology, Institut Jules Bordet, ULB, Brussels, Belgium |
| authorships[3].institutions[0].id | https://openalex.org/I2801838318 |
| authorships[3].institutions[0].ror | https://ror.org/05e8s8534 |
| authorships[3].institutions[0].type | healthcare |
| authorships[3].institutions[0].lineage | https://openalex.org/I2801838318 |
| authorships[3].institutions[0].country_code | BE |
| authorships[3].institutions[0].display_name | Institut Jules Bordet |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | P. Heimann |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Molecular Biology, Institut Jules Bordet, ULB, Brussels, Belgium |
| authorships[4].author.id | https://openalex.org/A5054937140 |
| authorships[4].author.orcid | |
| authorships[4].author.display_name | Marie Vercruyssen |
| authorships[4].countries | BE |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I2801838318 |
| authorships[4].affiliations[0].raw_affiliation_string | Hematology, Institut Jules Bordet, ULB, Brussels, Belgium |
| authorships[4].institutions[0].id | https://openalex.org/I2801838318 |
| authorships[4].institutions[0].ror | https://ror.org/05e8s8534 |
| authorships[4].institutions[0].type | healthcare |
| authorships[4].institutions[0].lineage | https://openalex.org/I2801838318 |
| authorships[4].institutions[0].country_code | BE |
| authorships[4].institutions[0].display_name | Institut Jules Bordet |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | M. Vercruyssen |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Hematology, Institut Jules Bordet, ULB, Brussels, Belgium |
| authorships[5].author.id | https://openalex.org/A5054772658 |
| authorships[5].author.orcid | |
| authorships[5].author.display_name | Chloé Spilleboudt |
| authorships[5].countries | BE |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I2801838318 |
| authorships[5].affiliations[0].raw_affiliation_string | Hematology, Institut Jules Bordet, ULB, Brussels, Belgium |
| authorships[5].institutions[0].id | https://openalex.org/I2801838318 |
| authorships[5].institutions[0].ror | https://ror.org/05e8s8534 |
| authorships[5].institutions[0].type | healthcare |
| authorships[5].institutions[0].lineage | https://openalex.org/I2801838318 |
| authorships[5].institutions[0].country_code | BE |
| authorships[5].institutions[0].display_name | Institut Jules Bordet |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | C. Spilleboudt |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Hematology, Institut Jules Bordet, ULB, Brussels, Belgium |
| authorships[6].author.id | https://openalex.org/A5021807846 |
| authorships[6].author.orcid | https://orcid.org/0000-0002-5413-0164 |
| authorships[6].author.display_name | Marie Maerevoet |
| authorships[6].countries | BE |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I2801838318 |
| authorships[6].affiliations[0].raw_affiliation_string | Hematology, Institut Jules Bordet, ULB, Brussels, Belgium |
| authorships[6].institutions[0].id | https://openalex.org/I2801838318 |
| authorships[6].institutions[0].ror | https://ror.org/05e8s8534 |
| authorships[6].institutions[0].type | healthcare |
| authorships[6].institutions[0].lineage | https://openalex.org/I2801838318 |
| authorships[6].institutions[0].country_code | BE |
| authorships[6].institutions[0].display_name | Institut Jules Bordet |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | M. Maerevoet |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Hematology, Institut Jules Bordet, ULB, Brussels, Belgium |
| authorships[7].author.id | https://openalex.org/A5044912720 |
| authorships[7].author.orcid | |
| authorships[7].author.display_name | Nathalie Meuleman |
| authorships[7].countries | BE |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I2801838318 |
| authorships[7].affiliations[0].raw_affiliation_string | Hematology, Institut Jules Bordet, ULB, Brussels, Belgium |
| authorships[7].institutions[0].id | https://openalex.org/I2801838318 |
| authorships[7].institutions[0].ror | https://ror.org/05e8s8534 |
| authorships[7].institutions[0].type | healthcare |
| authorships[7].institutions[0].lineage | https://openalex.org/I2801838318 |
| authorships[7].institutions[0].country_code | BE |
| authorships[7].institutions[0].display_name | Institut Jules Bordet |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | N. Meuleman |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Hematology, Institut Jules Bordet, ULB, Brussels, Belgium |
| authorships[8].author.id | https://openalex.org/A5035118381 |
| authorships[8].author.orcid | |
| authorships[8].author.display_name | Brigitte Cantinieaux |
| authorships[8].affiliations[0].raw_affiliation_string | Laboratory of Hematology, CHUB, ULB, Brussels, Belgium |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | B. Cantinieaux |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Laboratory of Hematology, CHUB, ULB, Brussels, Belgium |
| authorships[9].author.id | https://openalex.org/A5062814767 |
| authorships[9].author.orcid | https://orcid.org/0000-0002-6963-2968 |
| authorships[9].author.display_name | Stefan Michiels |
| authorships[9].countries | BE |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I2801838318 |
| authorships[9].affiliations[0].raw_affiliation_string | Hematology, Institut Jules Bordet, ULB, Brussels, Belgium |
| authorships[9].institutions[0].id | https://openalex.org/I2801838318 |
| authorships[9].institutions[0].ror | https://ror.org/05e8s8534 |
| authorships[9].institutions[0].type | healthcare |
| authorships[9].institutions[0].lineage | https://openalex.org/I2801838318 |
| authorships[9].institutions[0].country_code | BE |
| authorships[9].institutions[0].display_name | Institut Jules Bordet |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | S. Michiels |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | Hematology, Institut Jules Bordet, ULB, Brussels, Belgium |
| authorships[10].author.id | https://openalex.org/A5101761253 |
| authorships[10].author.orcid | https://orcid.org/0000-0002-1634-1104 |
| authorships[10].author.display_name | Dominique Bron |
| authorships[10].countries | BE |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I2801838318 |
| authorships[10].affiliations[0].raw_affiliation_string | Hematology, Institut Jules Bordet, ULB, Brussels, Belgium |
| authorships[10].institutions[0].id | https://openalex.org/I2801838318 |
| authorships[10].institutions[0].ror | https://ror.org/05e8s8534 |
| authorships[10].institutions[0].type | healthcare |
| authorships[10].institutions[0].lineage | https://openalex.org/I2801838318 |
| authorships[10].institutions[0].country_code | BE |
| authorships[10].institutions[0].display_name | Institut Jules Bordet |
| authorships[10].author_position | last |
| authorships[10].raw_author_name | D. Bron |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | Hematology, Institut Jules Bordet, ULB, Brussels, Belgium |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hon.2439_111 |
| open_access.oa_status | bronze |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Prognostic value of |
| has_fulltext | True |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10185 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9977999925613403 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2734 |
| primary_topic.subfield.display_name | Pathology and Forensic Medicine |
| primary_topic.display_name | Lymphoma Diagnosis and Treatment |
| related_works | https://openalex.org/W2563731036, https://openalex.org/W2317141594, https://openalex.org/W2539547228, https://openalex.org/W1969049855, https://openalex.org/W2045713409, https://openalex.org/W4232815876, https://openalex.org/W2115179216, https://openalex.org/W2164427041, https://openalex.org/W2329713498, https://openalex.org/W2049105081 |
| cited_by_count | 0 |
| locations_count | 1 |
| best_oa_location.id | doi:10.1002/hon.2439_111 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S23714410 |
| best_oa_location.source.issn | 0278-0232, 1099-1069 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 0278-0232 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Hematological Oncology |
| best_oa_location.source.host_organization | https://openalex.org/P4310320595 |
| best_oa_location.source.host_organization_name | Wiley |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320595 |
| best_oa_location.source.host_organization_lineage_names | Wiley |
| best_oa_location.license | |
| best_oa_location.pdf_url | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hon.2439_111 |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Hematological Oncology |
| best_oa_location.landing_page_url | https://doi.org/10.1002/hon.2439_111 |
| primary_location.id | doi:10.1002/hon.2439_111 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S23714410 |
| primary_location.source.issn | 0278-0232, 1099-1069 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 0278-0232 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Hematological Oncology |
| primary_location.source.host_organization | https://openalex.org/P4310320595 |
| primary_location.source.host_organization_name | Wiley |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320595 |
| primary_location.source.host_organization_lineage_names | Wiley |
| primary_location.license | |
| primary_location.pdf_url | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hon.2439_111 |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Hematological Oncology |
| primary_location.landing_page_url | https://doi.org/10.1002/hon.2439_111 |
| publication_date | 2017-06-01 |
| publication_year | 2017 |
| referenced_works_count | 0 |
| abstract_inverted_index.2 | 41 |
| abstract_inverted_index.> | 225, 285, 316 |
| abstract_inverted_index.a | 6, 179, 397, 404 |
| abstract_inverted_index.24 | 176 |
| abstract_inverted_index.30 | 173 |
| abstract_inverted_index.36 | 275, 357 |
| abstract_inverted_index.4% | 222 |
| abstract_inverted_index.57 | 304, 375 |
| abstract_inverted_index.58 | 297 |
| abstract_inverted_index.61 | 203 |
| abstract_inverted_index.62 | 189 |
| abstract_inverted_index.63 | 243, 355 |
| abstract_inverted_index.65 | 79, 237 |
| abstract_inverted_index.71 | 269 |
| abstract_inverted_index.E. | 100 |
| abstract_inverted_index.In | 193, 227, 260, 289 |
| abstract_inverted_index.OS | 241, 273, 302, 352, 374 |
| abstract_inverted_index.We | 75 |
| abstract_inverted_index.an | 328 |
| abstract_inverted_index.as | 416 |
| abstract_inverted_index.at | 118, 182, 186 |
| abstract_inverted_index.by | 152 |
| abstract_inverted_index.in | 14, 69, 83, 172, 255, 287, 359, 389, 408, 423 |
| abstract_inverted_index.is | 5, 66 |
| abstract_inverted_index.of | 16, 47, 57, 257, 322, 342, 348, 353, 370, 382, 411 |
| abstract_inverted_index.to | 99, 108, 122, 131, 401 |
| abstract_inverted_index.148 | 212 |
| abstract_inverted_index.30% | 286 |
| abstract_inverted_index.36% | 256 |
| abstract_inverted_index.40% | 313 |
| abstract_inverted_index.6+) | 265 |
| abstract_inverted_index.Cox | 153 |
| abstract_inverted_index.Low | 137, 363 |
| abstract_inverted_index.MCL | 80, 292, 343 |
| abstract_inverted_index.Mo, | 244, 276, 305 |
| abstract_inverted_index.Our | 339 |
| abstract_inverted_index.SUV | 216, 246, 278, 307, 379, 399 |
| abstract_inverted_index.The | 377 |
| abstract_inverted_index.age | 185, 201, 235, 267, 295 |
| abstract_inverted_index.and | 53, 73, 90, 104, 135, 138, 165, 175, 221, 251, 283, 312, 356, 362, 367, 393, 396 |
| abstract_inverted_index.era | 321, 410 |
| abstract_inverted_index.for | 86, 162 |
| abstract_inverted_index.had | 178, 223, 314, 327 |
| abstract_inverted_index.low | 195 |
| abstract_inverted_index.max | 217, 247, 279, 308, 380 |
| abstract_inverted_index.old | 300 |
| abstract_inverted_index.our | 84 |
| abstract_inverted_index.pts | 174, 177, 365 |
| abstract_inverted_index.the | 20, 28, 36, 45, 55, 70, 132, 145, 194, 228, 258, 261, 290, 320, 345, 383, 390, 409 |
| abstract_inverted_index.was | 120, 150, 170, 188, 202, 211, 218, 236, 242, 248, 253, 268, 274, 280, 296, 303, 309, 387 |
| abstract_inverted_index.(OS) | 210 |
| abstract_inverted_index.(med | 351, 373 |
| abstract_inverted_index.13.9 | 310 |
| abstract_inverted_index.148, | 354 |
| abstract_inverted_index.2.86 | 219 |
| abstract_inverted_index.30%. | 226, 317 |
| abstract_inverted_index.4-5) | 233 |
| abstract_inverted_index.57%. | 288 |
| abstract_inverted_index.6.31 | 249 |
| abstract_inverted_index.8.25 | 281 |
| abstract_inverted_index.>30% | 254 |
| abstract_inverted_index.Cell | 23 |
| abstract_inverted_index.Ki67 | 284, 315 |
| abstract_inverted_index.MCLs | 395 |
| abstract_inverted_index.MIPI | 33, 96, 133, 163, 349 |
| abstract_inverted_index.SUV. | 125, 147 |
| abstract_inverted_index.When | 113 |
| abstract_inverted_index.cell | 2, 428 |
| abstract_inverted_index.data | 92 |
| abstract_inverted_index.high | 391, 398 |
| abstract_inverted_index.mo). | 376 |
| abstract_inverted_index.old, | 206 |
| abstract_inverted_index.old. | 192 |
| abstract_inverted_index.poor | 368, 405 |
| abstract_inverted_index.pts. | 259 |
| abstract_inverted_index.risk | 37, 140, 196, 230, 392 |
| abstract_inverted_index.role | 46 |
| abstract_inverted_index.scan | 117, 181 |
| abstract_inverted_index.such | 415 |
| abstract_inverted_index.that | 27, 332 |
| abstract_inverted_index.then | 128 |
| abstract_inverted_index.thus | 76 |
| abstract_inverted_index.very | 412 |
| abstract_inverted_index.were | 93, 111, 127, 142, 160 |
| abstract_inverted_index.with | 10, 32, 144, 336, 403 |
| abstract_inverted_index.y.o, | 271 |
| abstract_inverted_index.(MCL) | 4 |
| abstract_inverted_index.(MIPI | 198, 264 |
| abstract_inverted_index.(Mo), | 214 |
| abstract_inverted_index.(PET) | 52 |
| abstract_inverted_index.(pts) | 159 |
| abstract_inverted_index.0-3), | 199 |
| abstract_inverted_index.2008) | 103 |
| abstract_inverted_index.BLOOD | 102 |
| abstract_inverted_index.High, | 136, 360 |
| abstract_inverted_index.Ki-67 | 29, 105, 167, 224, 252, 325 |
| abstract_inverted_index.after | 334 |
| abstract_inverted_index.data. | 18 |
| abstract_inverted_index.group | 197, 231, 263 |
| abstract_inverted_index.index | 30, 106, 168, 326 |
| abstract_inverted_index.level | 56 |
| abstract_inverted_index.risks | 364 |
| abstract_inverted_index.score | 164 |
| abstract_inverted_index.seems | 400 |
| abstract_inverted_index.small | 340 |
| abstract_inverted_index.terms | 15 |
| abstract_inverted_index.these | 40, 418 |
| abstract_inverted_index.value | 61, 169, 331, 347, 381 |
| abstract_inverted_index.wider | 424 |
| abstract_inverted_index.y.o., | 239 |
| abstract_inverted_index.years | 191, 205, 299 |
| abstract_inverted_index.(42-77 | 204 |
| abstract_inverted_index.(MCL); | 430 |
| abstract_inverted_index.(MIPI, | 232 |
| abstract_inverted_index.(PET); | 434 |
| abstract_inverted_index.(hyper | 63 |
| abstract_inverted_index.18-FDG | 115 |
| abstract_inverted_index.18-FGD | 385 |
| abstract_inverted_index.B-cell | 7 |
| abstract_inverted_index.Beside | 39 |
| abstract_inverted_index.Mantle | 1, 22 |
| abstract_inverted_index.Median | 184 |
| abstract_inverted_index.Months | 213 |
| abstract_inverted_index.PET/CT | 116, 180, 386 |
| abstract_inverted_index.allows | 34 |
| abstract_inverted_index.before | 319 |
| abstract_inverted_index.group, | 293 |
| abstract_inverted_index.groups | 141 |
| abstract_inverted_index.higher | 388 |
| abstract_inverted_index.highly | 11 |
| abstract_inverted_index.mantle | 427 |
| abstract_inverted_index.median | 200, 207, 215, 234, 240, 245, 266, 272, 277, 294, 301, 306, 378 |
| abstract_inverted_index.model. | 155 |
| abstract_inverted_index.months | 358 |
| abstract_inverted_index.poorly | 67 |
| abstract_inverted_index.scores | 97, 134, 350 |
| abstract_inverted_index.series | 341 |
| abstract_inverted_index.uptake | 60 |
| abstract_inverted_index.(40-77) | 298 |
| abstract_inverted_index.(40-85) | 190 |
| abstract_inverted_index.(47-85) | 270 |
| abstract_inverted_index.(54-79) | 238 |
| abstract_inverted_index.Hoster, | 101 |
| abstract_inverted_index.Network | 25 |
| abstract_inverted_index.Overall | 148 |
| abstract_inverted_index.indices | 436 |
| abstract_inverted_index.initial | 384 |
| abstract_inverted_index.markers | 420 |
| abstract_inverted_index.maximal | 124 |
| abstract_inverted_index.maximum | 58, 146 |
| abstract_inverted_index.outcome | 369 |
| abstract_inverted_index.overall | 208 |
| abstract_inverted_index.series. | 425 |
| abstract_inverted_index.(SUVmax) | 62 |
| abstract_inverted_index.European | 21 |
| abstract_inverted_index.However, | 407 |
| abstract_inverted_index.Lymphoma | 24 |
| abstract_inverted_index.Methods: | 74 |
| abstract_inverted_index.Patients | 126 |
| abstract_inverted_index.Results: | 156 |
| abstract_inverted_index.admitted | 82 |
| abstract_inverted_index.combined | 31 |
| abstract_inverted_index.confirms | 344 |
| abstract_inverted_index.deserves | 421 |
| abstract_inverted_index.emission | 50, 432 |
| abstract_inverted_index.factors, | 44 |
| abstract_inverted_index.lymphoma | 3, 9, 429 |
| abstract_inverted_index.outcome, | 166 |
| abstract_inverted_index.outcome. | 406 |
| abstract_inverted_index.patients | 81, 158 |
| abstract_inverted_index.positron | 431 |
| abstract_inverted_index.refining | 35 |
| abstract_inverted_index.reported | 26 |
| abstract_inverted_index.reviewed | 78, 121 |
| abstract_inverted_index.survival | 17, 149, 209 |
| abstract_inverted_index.variable | 12 |
| abstract_inverted_index.(2.0-8.4) | 220 |
| abstract_inverted_index.Ibrutinib | 323 |
| abstract_inverted_index.Institute | 85 |
| abstract_inverted_index.Keywords: | 426 |
| abstract_inverted_index.Recently, | 19 |
| abstract_inverted_index.according | 130 |
| abstract_inverted_index.activity) | 65 |
| abstract_inverted_index.anti-BTK. | 337 |
| abstract_inverted_index.available | 171 |
| abstract_inverted_index.behaviors | 13 |
| abstract_inverted_index.blastoïd | 371, 394 |
| abstract_inverted_index.correlate | 402 |
| abstract_inverted_index.determine | 123 |
| abstract_inverted_index.diagnosis | 119, 187 |
| abstract_inverted_index.effective | 413 |
| abstract_inverted_index.evaluable | 161 |
| abstract_inverted_index.evaluated | 151 |
| abstract_inverted_index.high-risk | 262 |
| abstract_inverted_index.histology | 372 |
| abstract_inverted_index.metabolic | 64 |
| abstract_inverted_index.primarily | 54 |
| abstract_inverted_index.published | 109 |
| abstract_inverted_index.reviewed. | 95 |
| abstract_inverted_index.treatment | 335, 414 |
| abstract_inverted_index.(2.0-15.6) | 282 |
| abstract_inverted_index.(2.6-23.1) | 311 |
| abstract_inverted_index.(4.7-10.4) | 250 |
| abstract_inverted_index.(according | 98, 107 |
| abstract_inverted_index.Ibrutinib, | 417 |
| abstract_inverted_index.Population | 72 |
| abstract_inverted_index.available, | 114 |
| abstract_inverted_index.correlated | 143 |
| abstract_inverted_index.diagnosis. | 183 |
| abstract_inverted_index.disappears | 333 |
| abstract_inverted_index.prognostic | 43, 330, 346, 419, 435 |
| abstract_inverted_index.regression | 154 |
| abstract_inverted_index.stratified | 129 |
| abstract_inverted_index.tomography | 51, 433 |
| abstract_inverted_index.treatment, | 324 |
| abstract_inverted_index.treatment. | 87 |
| abstract_inverted_index.Conclusion: | 338 |
| abstract_inverted_index.Fifty-three | 157 |
| abstract_inverted_index.calculated. | 112 |
| abstract_inverted_index.cytogenetic | 91 |
| abstract_inverted_index.guidelines) | 110 |
| abstract_inverted_index.independent | 329 |
| abstract_inverted_index.literature. | 71 |
| abstract_inverted_index.non-Hodgkin | 8 |
| abstract_inverted_index.confirmation | 422 |
| abstract_inverted_index.intermediate | 139, 229, 361 |
| abstract_inverted_index.investigated | 68 |
| abstract_inverted_index.phenotypical | 89 |
| abstract_inverted_index.standardized | 59 |
| abstract_inverted_index.Interestingly | 318 |
| abstract_inverted_index.Introduction: | 0 |
| abstract_inverted_index.Pathological, | 88 |
| abstract_inverted_index.complementary | 42 |
| abstract_inverted_index.independently | 94 |
| abstract_inverted_index.respectively) | 366 |
| abstract_inverted_index.(FDG)-positron | 49 |
| abstract_inverted_index.retrospectively | 77 |
| abstract_inverted_index.stratification. | 38 |
| abstract_inverted_index.“blastoïd” | 291 |
| abstract_inverted_index.18-fluorodeoxyglucose | 48 |
| cited_by_percentile_year | |
| countries_distinct_count | 1 |
| institutions_distinct_count | 11 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.699999988079071 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.07853114 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |